01642nas a2200337   4500000000100000008004100001260001700042653001100059653002900070653001600099653002800115653001200143653003000155653001900185653001600204653002200220653001100242653001200253653001500265653001300280653000900293100001200302700001100314700001100325245010600336300001000442490000700452050003200459520079900491022001401290       1987                            d  c1987 Jan-Mar10aBiopsy10aClinical Trials as Topic10aClofazimine10aCosts and Cost Analysis10aDapsone10aDrug Therapy, Combination10aDrug Tolerance10aEthionamide10aFollow-Up Studies10aHumans10aleprosy10aRecurrence10aRifampin10aSkin1 aKumar B1 aKaur S1 aKaur I00aShort term combination therapy for paucibacillary leprosy--histological evaluation & follow-up study.  a54-620 v59  aInfolep Library - available3 a<p>68 patients with paucibacillary disease were started on various regimes of multi drug therapy, consisting of ethionamide, rifampicin or clofazimine administered with dapsone. Serial skin biopsies were taken from 32 patients at one, two and three years and even later after the initial pre treatment biopsy. Actual material was available for study from 9 patients. All regimens were tolerated well except the one with ethionamide. However the therapeutic response was equal in all combination therapies as supported by histopathology. Compared to that with dapsone monotherapy the response was quicker with combination. Dapsone plus rifampicin combination was best tolerated and it worked out to be economical as well. No relapse was noted in any group during two or more years follow up.</p>  a0254-9395